Matinas BioPharma Nanotechnologies, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2013-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.aquariusbio.com
Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial 3
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-09-15
- Last Posted Date
- 2022-09-15
- Lead Sponsor
- Matinas BioPharma Nanotechnologies, Inc.
- Target Recruit Count
- 270
- Registration Number
- NCT05541107
Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-11-26
- Last Posted Date
- 2022-03-04
- Lead Sponsor
- Matinas BioPharma Nanotechnologies, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT04177680
- Locations
- 🇺🇸
Matinas Investigational Site, Chicago, Illinois, United States
🇺🇸Matinas Investigational site, Richmond, Virginia, United States
Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial (EnACT)
- First Posted Date
- 2019-07-24
- Last Posted Date
- 2023-03-31
- Lead Sponsor
- Matinas BioPharma Nanotechnologies, Inc.
- Target Recruit Count
- 178
- Registration Number
- NCT04031833
- Locations
- 🇺🇬
Infectious Disease Institute, Kampala, Uganda
Efficacy and Safety of Oral Encochleated Amphotericin B for the Treatment of Cryptococcal Infection
- First Posted Date
- 2017-06-23
- Last Posted Date
- 2019-03-08
- Lead Sponsor
- Matinas BioPharma Nanotechnologies, Inc.
- Registration Number
- NCT03196921
Safety and PK of Oral Encochleated Amphotericin B (CAMB/MAT2203) for Antifungal Prophylaxis in Patients Undergoing Induction Chemotherapy for Acute Myelogenous and Lymphoblastic Leukaemia
Phase 2
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2017-06-15
- Last Posted Date
- 2019-03-08
- Lead Sponsor
- Matinas BioPharma Nanotechnologies, Inc.
- Registration Number
- NCT03187691
Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis
Phase 2
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2019-03-08
- Lead Sponsor
- Matinas BioPharma Nanotechnologies, Inc.
- Registration Number
- NCT03167957
- Locations
- 🇺🇸
Tolan Park Clinic, Detroit, Michigan, United States
Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-11-22
- Last Posted Date
- 2018-11-02
- Lead Sponsor
- Matinas BioPharma Nanotechnologies, Inc.
- Target Recruit Count
- 137
- Registration Number
- NCT02971007
- Locations
- 🇺🇸
Lawrence OB/GYN, Lawrenceville, New Jersey, United States
🇺🇸Advanced Research Institute Inc, New Port Richey, Florida, United States
🇺🇸PMG Research of Wilmington, LLC, Wilmington, North Carolina, United States
CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis
- First Posted Date
- 2015-12-14
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Matinas BioPharma Nanotechnologies, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT02629419
- Locations
- 🇺🇸
National Institute of Allergy and Infectious Disease (NIAID), Bethesda, Maryland, United States
© Copyright 2024. All Rights Reserved by MedPath